FDA Inspection 1255845 — Natasha Leighl, M.D.
The FDA completed an inspection of Natasha Leighl, M.D. on Nov 22, 2024 in Toronto. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 22, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Toronto (Canada)
Additional Details
Clinical BA/BE
Citations
| ID | CFR | Description |
|---|---|---|
| 7666 | 21 CFR 50.20 | Understandable language |